The abstract is read at the publisher; the summary is JClub's.
In UK Biobank and Geisinger MyCode, germline PALB2 P/LP heterozygosity is linked to higher odds of any cancer, female breast cancer, and pancreatic cancer, with adjusted hazard ratios up to 3.6.
- Why it matters: Familial ascertainment has been studied, but population-based genomic ascertainment is needed to quantify age-specific penetrance and mortality without selection from personal or family history.
- What they did: In two adult cohorts (UK Biobank n=469,580; Geisinger MyCode n=167,050), exome sequencing identified PALB2 P/LP heterozygotes and non-carriers; logistic regression estimated cancer odds and Cox models estimated mortality, with Kaplan-Meier penetrance.
- The result: PALB2 P/LP prevalence was 1:571 in UK Biobank and 1:940 in MyCode; compared with non-carriers, heterozygotes had increased cancer odds (P<0.01), higher all-cause mortality (HR 1.61–1.67), and reduced survival after diagnosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.